Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 0.54 |
| ▸ | KDR | P35968 | 10/20 | 0.54 |
| ▸ | CSK | P41240 | 2/20 | 0.48 |
| ▸ | TEK | Q02763 | 2/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 5/20 | 0.44 |
| ▸ | KIF5B | P33176 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029134 | 0.92 | SRC (0.56) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4028028 | 0.90 | SRC (0.56) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4025140 | 0.89 | SRC (0.69) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4025187 | 0.86 | SRC (0.52) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4028008 | 0.84 | SRC (0.54) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4024733 | 0.82 | SRC (0.57) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4023466 | 0.82 | SRC (0.54) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4030606 | 0.81 | SRC (0.56) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL4026178 | 0.81 | SRC (0.69) | SRCKDRCSKTEKEPHB4 | |
| SCHEMBL6168041 | 0.81 | SRC (0.51) | SRCKDRCSKTEKEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | disclosed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | SRC 1917/4885KDR 2563/4885CSK 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.